Mitochondria autophagy: a potential target for cancer therapy. (3rd July 2021)

• Record Type: Journal Article
• Authors: Qiu, Yu-Han; Zhang, Tian-Shu; Wang, Xiao-Wei; Wang, Meng-yan; Zhao, Wen-Xia; Zhou, Hui-Min; Zhang, Cong-Hui; Cai, Mei-Lian; Chen, Xiao-Fang; Zhao, Wu-Li; Shao, Rong-Guang
• Is Part Of: Journal of drug targeting. Volume 29:Number 6(2021)
• Page Start: 576
• Page End: 591
• Publication Date: 2021-07-03
• Subjects: Mitophagy -- cancer -- LC3 -- PINK1 -- parkin; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2020.1867992
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Mitophagy is a selective form of macroautophagy in which dysfunctional and damaged mitochondria can be efficiently degraded, removed and recycled through autophagy. Selective removal of damaged or fragmented mitochondria is critical to the functional integrity of the entire mitochondrial network and cells. In past decades, numerous studies have shown that mitophagy is involved in various diseases; however, since the dual role of mitophagy in tumour development, mitophagy role in tumour is controversial, and further elucidation is needed. That is, although mitophagy has been demonstrated to contribute to carcinogenesis, cell migration, ferroptosis inhibition, cancer stemness maintenance, tumour immune escape, drug resistance, etc. during cancer progression, many research also shows that to promote cancer cell death, mitophagy can be induced physiologically or pharmacologically to maintain normal cellular metabolism and prevent cell stress responses and genome damage by diminishing mitochondrial damage, thus suppressing tumour development accompanying these changes. Signalling pathway-specific molecular mechanisms are currently of great biological significance in the identification of potential therapeutic targets. Here, we review recent progress of molecular pathways mediating mitophagy including both canonical pathways (Parkin/PINK1- and FUNDC1-mediated mitophagy) and noncanonical pathways (FKBP8-, Nrf2-, and DRP1-mediated mitophagy); and the regulation of these pathways, and abovementioned pro-cancer and pro-death roles of mitophagy. Finally, we summarise the role of mitophagy in cancer therapy. Mitophagy can potentially be acted as the target for cancer therapy by promotion or inhibition.